SCHEMBL660313

SCHEMBL660313

Cc1ccc(N2C(=O)NC(=O)C23CCN(C(=O)OC(C)(C)C)CC3)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.52
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCR5 P51681 2/20 0.43
NPBWR1 P48145 1/20 0.42
MCHR1 Q99705 1/20 0.42
TP53 P04637 1/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
USP30 Q70CQ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17149526 0.89 CCR5 (0.53) GPR119KMT2AMEN1CYP2C19CCR5
SCHEMBL18973064 0.88 CCR5 (0.44) GPR119KMT2AMEN1CYP2C19SMN1; SMN2
SCHEMBL17140779 0.88 ALDH1A1 (0.48) GPR119SMN1; SMN2CCR5TP53LMNA
SCHEMBL17140762 0.86 PKM (0.46) GPR119KMT2AMEN1CYP2C19SMN1; SMN2
SCHEMBL17149468 0.85 MAPT (0.61) GPR119SMN1; SMN2CCR5TP53LMNA
SCHEMBL17127587 0.85 CCR5 (0.41) GPR119KMT2AMEN1CCR5LMNA
SCHEMBL17141140 0.82 SMARCA2 (0.40) GPR119CCR5LMNAMAPTALDH1A1
SCHEMBL659257 0.82 GAA (0.42) KMT2AMEN1CYP2C19SMN1; SMN2LMNA
SCHEMBL25251398 0.81 GRM5 (0.45) GPR119CYP2C19CCR5TP53LMNA
SCHEMBL30382141 0.81 GRM5 (0.45) GPR119CYP2C19CCR5TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120045500-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045500-A1 NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM SOAT1, SOAT2, ODC1 GPR119 500/4885KMT2A 611/4885MEN1 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.